Please assess the completion status of the following clinical trial:

Trial Title: A Study of Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria~Females age 18 years or older at the time of informed consent~Have histologically or cytologically proven adenocarcinoma of the breast~Subjects with locally recurrent or metastatic disease with at least one measurable lesion according to Response Evaluation Criteria in Solid Tumors~(RECIST) criteria v 1.1~Human epidermal growth factor receptor (HER2)-negative disease as determined by fluorescence in situ hybridization (FISH) or 0 or 1+ by immunohistochemical (IHC) staining.~Life expectancy of greater than 24 weeks~Eastern Cooperative Oncology Group (ECOG) Performance Score (PS) of 0, 1 or 2~At least 12 months since prior neoadjuvant or adjuvant chemotherapy~At least 2 weeks since prior radiotherapy or endocrine therapy, with complete recovery from the effects of these interventions~Adequate renal function~Adequate bone marrow function~Adequate liver function~Key Exclusion Criteria~Subjects who meet any of the following criteria will be excluded from participation in this study:~Prior chemotherapy, biologic therapy, or investigational therapy for locally recurrent or metastatic breast cancer~Subjects who have had a prior malignancy other than carcinoma in situ of the cervix or nonmelanoma skin cancer~Prior exposure of greater than 360 mg/m2 doxorubicin or liposomal doxorubicin, greater than 120 mg/m2 mitoxantrone, greater than 90 mg/m2 idarubicin, or greater than720 mg/m2 epirubicin~Inflammatory breast cancer~Clinically significant cardiovascular impairment~Subjects with known CNS disease are not eligible, except for those with treated brain metastasis.~Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring the use of oxygen~Currently pregnant or breast-feeding.~Subjects with pre-existing Grade 3 or 4 neuropathy. Any peripheral neuropathy must recover to Grade 2 before enrollment.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).